PaulF. Pathology and MRI: Exploring cognitive impairment in MS. Acta Neurol Scand2016; 134(Suppl. 200): 24–33.
2.
BenedictRHBZivadinovR. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol2011; 7: 332–342.
3.
Di FilippoMPortaccioEManciniA, et al. Multiple sclerosis and cognition: Synaptic failure and network dysfunction. Nat Rev Neurosci2018; 19(10): 599–609.
4.
SpelmanTMagyariMPiehlF, et al. Treatment escalation versus immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: Data from 2 different national strategies. JAMA Neurol2021; 78: 1197–1204.
5.
CarlomagnoVMirabellaMLucchiniM. Current status of oral disease-modifying treatment effects on cognitive outcomes in multiple sclerosis: A scoping review. Bioengineering2023; 10(7): 848.
6.
FengGPosaSSureshkumarA, et al. Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: A systematic review and meta-aggregation. J Neurol2024; 271(3): 1084–1107.
7.
WillsOProbstYHaartsenJ, et al. The role of multidisciplinary MS care teams in supporting lifestyle behaviour changes to optimise brain health among people living with MS: A qualitative exploration of clinician perspectives. Health Expect2024; 27(2): e14042.
8.
SteinCO’KeeffeFStrahanO, et al. Systematic review of cognitive reserve in multiple sclerosis: Accounting for physical disability, fatigue, depression, and anxiety. Mult Scler Relat Disord2023; 79: 105017.
9.
ArtemiadisABakirtzisCIfantopoulouP, et al. The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients. Mult Scler Relat Disord2020; 41: 102047.
10.
SaposnikGOhJTerzaghiMA, et al. Emotional expressions associated with therapeutic inertia in multiple sclerosis care. Mult Scler Relat Disord2019; 34: 17–28.
